πŸ‡ΊπŸ‡Έ FDA
Patent

US 11198699

Compounds targeting PRMT5

granted A61KA61K31/437A61K31/519

Quick answer

US patent 11198699 (Compounds targeting PRMT5) held by Aligos Therapeutics, Inc. expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aligos Therapeutics, Inc.
Grant date
Tue Dec 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K31/437, A61K31/519, A61K31/52, A61K31/522